CA-XSOLLA
16.7.2024 14:01:35 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of Xsolla Backend, an innovative solution designed to help developers of all sizes, especially indie and midsize teams, work across various gaming platforms. Xsolla Backend makes their games more accessible by allowing developers to unite their audience across all platforms: PC, console, mobile, and the web. This addresses audience fragmentation common to most games and enables developers to save costs while creating deeper engagement as they grow their gaming business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716151058/en/
(Graphic: Xsolla)
Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes streamlined account management, efficient matchmaking, dynamic questing systems, and robust cross-play and multiplayer functionalities. These features ensure a more connected and immersive gaming experience, allowing developers to focus more on the creative aspects of game development while minimizing technical complexities. The vertically integrated solution enables cross-play and cross-pay across all platforms, seamlessly integrated with Xsolla game commerce solutions.
Jean-Philippe Steinmetz, Head of Xsolla Backend, states, "With Xsolla Backend, we are democratizing backend technology, ensuring developers of all sizes can access advanced tools needed to create compelling, immersive gaming experiences."
Following the strategic acquisition of the award-winning AcceleratXR technology in 2023, Xsolla Backend is designed to handle the majority of game backend needs from the outset while providing developers the flexibility to customize as needed. The platform operates on a no-upfront fee model, charging only a 5% royalty, including backend hosting, making it financially accessible and beneficial for developers of all sizes.
With over 30 active partners and more than ten in-development projects, Xsolla Backend is proving to be a game-changer in the industry. Developers interested in experiencing Xsolla Backend firsthand can demo the platform at Gamescom in Cologne this August.
David Stelzer, President of Xsolla, highlights, "Our business model and robust platform design align our success with that of our partners. Xsolla Backend is not just technology but a partnership that grows with developers, supported by ongoing enhancements and a roadmap filled with powerful updates."
Later this year, Xsolla Backend will introduce new SDKs for platforms like Microsoft Xbox and Sony PlayStation, enhancing our support for major gaming systems. The expansion will also include a self-service portal, social launcher, and updates to the admin console for more efficient game management. Developers can also look forward to integrating Xsolla Payment Systems, all of which will comply with industry regulations and maintain Xsolla's standard of regulatory adherence. Additional updates will feature a party system, gameplay collectibles, tournament systems, loot boxes, and multiplayer voice chat, further enriching the gaming experience while ensuring compliance.
For more information about Xsolla Backend or to sign up, visit xsolla.pro/xbe and Discord: xsolla.pro/xbe-discord
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716151058/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom